

ICMJE DISCLOSURE FORM

Date: November 15, 2023

Your Name: Cindy Nguyen

Manuscript Title: Prevalence and Characteristics of Patients Prescribed Opioids and Central Nervous System Depression Agents on Discharge to Hospice Care

Manuscript number (if known): APM-23-537-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

None.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: _____ December 12, 2023 _____
 Your Name: _____ Mary Lynn McPherson, PharmD, PhD, BCPS _____
 Manuscript Title: Prevalence and Characteristics of Patients Prescribed Opioids and Central Nervous System Depression Agents on Discharge to Hospice Care
 Manuscript number (if known): _____ APM-23-537-CL _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	___ None	
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

N/A

Please place an "X" next to the following statement to indicate your agreement:

 x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 11/27/23
 Your Name: BrieNoble
 Manuscript Title: Prevalence and Characteristics of Patients Prescribed Opioids and Central Nervous System Depression Agents on Discharge to Hospice Care
 Manuscript number (if known): APM-23-537-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u>X</u> None	
6	Payment for expert testimony	<u>X</u> None	
7	Support for attending meetings and/or travel	<u>X</u> None	
8	Patents planned, issued or pending	<u>X</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u>X</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>X</u> None	
11	Stock or stock options	<u>X</u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>X</u> None	
13	Other financial or non-financial interests	<u>X</u> None	

Please summarize the above conflict of interest in the following box:

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 11/19/2023

Your Name: Jon P. Furuno, PhD

Manuscript Title: Prevalence and Characteristics of Patients Prescribed Opioids and Central Nervous System Depression Agents on Discharge to Hospice Care

Manuscript number (if known): APM-23-537-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u> X </u> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u> </u> None	AHRQ R01HS027820. Developing a novel antibiogram tool to improve empiric antibiotic prescribing in nursing homes. This is a multi-site project using a mixed methods approach to develop, implement, and evaluate novel antibiograms to improve antibiotic prescribing in nursing homes.

			<p>Agency for Healthcare Research and Quality R01HS026747. Optimizing antibiotic prescribing on discharge to long-term care facilities. This project utilizes a mixed methods approach to develop interventions to improve antibiotic prescribing among hospitalized inpatients on discharge to nursing homes.</p>
			<p>Centers for Disease Control and Prevention Contract 75D30122F00001. Nursing home public health response network. This is a multisite study to develop knowledge and infrastructure to respond to public health emergencies in the nursing home setting.</p>
			<p>National Institutes of Health R01AG079555. Decision trajectories of patients at the end of life: An epidemiological exploration of MAID and the impact on caregivers and clinicians This is a multisite longitudinal cohort study to understand quantitative and qualitative outcomes of seriously ill persons pursuing MAID as well as their caregivers, and health care providers.</p>
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> None	
		Oregon Hospice and Palliative Care Association	Member, Board of Directors (unpaid)

		American Academy of Hospice and Palliative Medicine (AAHPM)	Member, DEI Committee (unpaid) Editor, DEI LAB, AAHPM Quarterly (unpaid)
		Society of Healthcare Epidemiology of America	Member, eLearning CE Subcommittee (unpaid) Statistical Consultant, Infection Control and Hospital Epidemiology (paid)
		Annals of Palliative Medicine	Member, Editorial Board (unpaid)
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

Jon P. Furuno serves as an unpaid editorial board member of *Annals of Palliative Medicine* from June 2023 to May 2025, an unpaid board member of Oregon Hospice and Palliative Care Association, unpaid member of Diversity, Equity, and Inclusion Committee and editor of Diversity, Equity, and Inclusion LAB of the American Academy of Hospice and Palliative Medicine, and unpaid member of eLearning Continuing Education subcommittee and paid Statistical of the Society of Healthcare Epidemiology of America. Jon P. Furuno received research funding from federal sponsors for other activities: First, AHRQ R01HS027820. This is a multi-site project using a mixed methods approach to develop, implement, and evaluate novel antibiograms to improve antibiotic prescribing in nursing homes, developing a novel antibiogram tool to improve empiric antibiotic prescribing in nursing homes. Second, Agency for Healthcare Research and Quality R01HS026747. This project utilizes a mixed methods approach to develop interventions to improve antibiotic prescribing among hospitalized inpatients on discharge to nursing homes, optimizing antibiotic prescribing on discharge to long-term care facilities. Third, Centers for Disease Control and Prevention Contract 75D30122F00001. This is a multisite study to develop knowledge and infrastructure to respond to public health emergencies in the nursing home setting, and nursing home public health response network. Last, National Institutes of Health R01AG079555. This is for Decision trajectories of patients at the end of life: An epidemiological exploration of MAID and the impact on caregivers and clinicians. This is a multisite longitudinal cohort study to understand quantitative and qualitative outcomes of seriously ill persons pursuing MAID as well as their caregivers, and health care providers. None represent any conflicts of interest related to this article.

Please place an “X” next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.